Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bellwyck to buy Patheon secondary clinical packaging and distribution business
Patheon chief executive officer James Mullen said that Patheon is happy to have reached an agreement with Bellwyck for the business. "While we don’t expect the terms of
Patheon chief executive officer James Mullen said that Patheon is happy to have reached an agreement with Bellwyck for the business. "While we don’t expect the terms of
Wockhardt has announced the immediate launch of Bupropion, the generic version of Glaxo Smithkline’s Wellbutrin SR, which it will manufacture at its facility in Waluj, India. The technology
Alvine is at present conducting Phase 2 trials with ALV003, an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease and a prolyl endopeptidase, in conjunction
The new plant will serve processors of infant formula, beverage, baby food and other food products in Asia Pacific. LycoRed sales and marketing VP Ilan Ron said LycoRed
The OmniRat technology generates fully human antibodies with specificity, affinity and manufacturability, according to WuXi. The technology eradicates time-consuming humanization of traditional mouse-derived antibodies and the need to
Mylan CEO Heather Bresch said Mylan’s mission is to provide the world’s 7 billion people access to medicines and help ensure access to ARVs. ”Only through access to
Bosulif is a kinase inhibitor that stops the cancer cell growth by inhibiting the Abl and Src signaling pathways. The drug is the only therapy approved with pivotal
The GOBIOM is a collection of 15,500 clinically evaluated, exploratory and preclinical biomarkers associated with diverse therapeutic areas reported in global clinical trials, clinical and preclinical studies. GVK
Previously, Clarke served as the company’s chief scientific officer and vice president of research and development, where he was involved in developing iCALM and iSPERSE technologies, designed for
A cyclosporine derivative, SCY-641, is the first partnered compound from the Scynexis cyclophilin inhibitor platform, which includes a clinical candidate for the treatment of Hepatitis C, SCY-635. Scynexis